VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) today announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). March marks the third consecutive month of record enrollment for CEL-SCI this year following January and February 2015. 406 patients have been enrolled in the Phase III study as of March 31, 2015.

“The accelerating pace of enrollment in our trial is very good. We expect to see continued increases in monthly patient enrollment throughout the year as new clinical centers are added and as existing centers gain more experience with Multikine,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

WILMINGTON, Mass., March 26, 2015 /PRNewswire/ — Implant Sciences Corporation (IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today reported the shipment of approximately $500,000 in explosives trace detection systems in Latin America, most of which were sold to a major international airline in Latin America.

“Implant Sciences continues to expand its market share in the Latin American aviation security space. We believe that the combination of our superior performance and value proposition is the impetus behind this success, which could also set the stage for follow-on orders from these customers,” stated Dr. Darryl Jones, Implant Sciences’ Global Vice President of Sales and Marketing. “We are seeing a significant increase in demand for our products since our recent checkpoint certifications from the US Transportation Security Administration (TSA) and the European Civil Aviation Conference (ECAC).”

“Our QS-B220 is specifically designed to meet the needs of aviation-related applications, including passenger, baggage, and cargo screening. As the only non-radioactive ETD in the world to pass the latest testing protocols of both TSA and ECAC, the QS-B220 is becoming the ETD of choice for a larger number of purchasers in the aviation security market,” added Dr. Bill McGann, CEO of Implant Sciences.

JERUSALEM, April 1, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the first patient has been enrolled in its Glucose Clamp Study. The study will be performed at The University of Texas Health Science Center at San Antonio and University Health System’s Texas Diabetes Institute under the supervision of Professor Ralph DeFronzo.

The glucose clamp is a method for quantifying insulin absorption in order to measure a patient’s insulin sensitivity and how well a patient metabolizes glucose. The glucose clamp technique represents the gold standard for pharmacodynamic studies in diabetes drug development.

In addition to the clamp study, Oramed plans to initiate its Phase IIb oral insulin trial in the U.S. with a protocol which includes over 30 U.S. sites covering approximately 180 patients and has both efficacy and safety as its primary end-points.

“We are pleased to have initiated this study and enrolled the first patient. We are additionally excited at the prospects of starting our larger Phase IIb trial in the near term. The data from the two trials will allow for a clearer picture of our oral insulin and its pharmacological characteristics as we move forward with our development plan,” stated Oramed CEO Nadav Kidron.